This week’s Vaccines Research update highlights regulatory momentum, clinical progress, early-stage pipeline expansion, and setbacks shaping global vaccine development.
In Today’s Newsletter
Dive deeper
🦟 Takeda Qdenga recommended for India import approval [1] [India • 30 Mar 2026]
https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/takeda-gets-expert-committee-nod-for-dengue-vaccine-approval-in-india/129900437
Context: The source says Qdenga is intended for ages 4–60 in India, and cites global Phase 3 data plus a local Phase 3 study indicating safety and immunogenicity.
Key point: Takeda’s Qdenga (dengue tetravalent vaccine) received a positive recommendation from India’s Subject Expert Committee for import approval, subject to a post-marketing local safety and effectiveness study within six months of market entry.
Implication: May expand screening, initiation, and follow-up at scale.
👶 MVC files Malaysia NDA for ENVACGEN [2] [Malaysia • 30 Mar 2026]
https://www.manilatimes.net/2026/03/30/tmt-newswire/pr-newswire/mvc-submits-nda-for-envacgen-in-malaysia-extending-taiwans-successful-experience-to-the-asean-market/2310186/amp
Context: The source attributes efficacy, infant eligibility from 2 months, and antibody persistence to company-reported Phase 3 and follow-up data.
Key point: MVC submitted a New Drug Application in Malaysia for ENVACGEN, its Enterovirus 71 vaccine, after prior approvals and launches in Taiwan and Vietnam.
Implication: May expand screening, initiation, and follow-up at scale.
🧬 Tonix advances TNX-4800 for Lyme prevention [3] [US • 31 Mar 2026]
https://www.globenewswire.com/news-release/2026/03/31/3265326/28908/en/Tonix-Pharmaceuticals-Announces-Presentation-of-Phase-1-Data-and-Outlines-Planned-Adaptive-Phase-2-Field-Study-of-TNX-4800-for-the-Prevention-of-Lyme-Disease-at-the-World-Vaccine-C.html
Context: The Phase 1 study enrolled 44 healthy adults, and Tonix said it plans a randomized, placebo-controlled adaptive Phase 2 field study in 1H 2027, pending FDA clearance.
Key point: Tonix reported Phase 1 data for TNX-4800, a long-acting anti-Borrelia burgdorferi monoclonal antibody, showing safety, tolerability, and PK supportive of about four months of protection.
Implication: May influence prescriber choice and payer reviews pending full data.
🧪 IO Biotech winds down after Cylembio setback [4] [31 Mar 2026]
https://www.biospace.com/business/io-shuts-down-following-regulatory-roadblocks Context: The source links the collapse to a Phase 3 study in frontline advanced melanoma that missed its primary endpoint for Cylembio plus Keytruda (pembrolizumab).
Key point: IO Biotech is shutting down operations and filed for Chapter 7 bankruptcy after the FDA advised against an approval filing for Cylembio in advanced melanoma.
Implication: Signals how regulatory risk can abruptly reset late-stage oncology programs and financing options.
💉 Delonix starts first-in-human Phase 1 for DX-104 [5] [Australia • 31 Mar 2026]
https://delonixbio.com/news/31?lang=en
Context: The randomized, double-blinded, positive-controlled study is underway in Perth, Australia, and has moved beyond sentinel safety review into broader enrollment.
Key point: Delonix Bioworks initiated first-in-human dosing in a Phase 1 trial of DX-104, its next-generation MenB OMV vaccine candidate.
Implication: Signals pipeline investment and modality expansion.
🧫 GC Biopharma gains Vietnam Phase 3 approval for BARYCELA [6] [Vietnam • 01 Apr 2026]
https://www.thebionews.net/news/articleViewAmp.html?idxno=23307
Context: The source says first patient in occurred on 17 Mar 2026, and the study compares BARYCELA with Varivax in children aged 12 months to 12 years.
Key point: GC Biopharma received Vietnam Ministry of Health approval to run a Phase 3 trial of BARYCELA, its two-dose varicella vaccine.
Implication: May influence prescriber choice and payer reviews pending full data.
🎗️ Anixa moves breast cancer vaccine toward Phase 2 [7] [US • 01 Apr 2026]
https://ir.anixa.com/press-releases/detail/1117/anixa-biosciences-advances-breast-cancer-vaccine-toward
Context: Anixa said final Phase 1 results met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants.
Key point: Anixa Biosciences advanced its α-lactalbumin-targeting breast cancer vaccine toward Phase 2 and selected Cytovance Biologics to manufacture cGMP clinical materials.
Implication: Signals pipeline investment and modality expansion.
Why it matters
- Asia vaccine activity was prominent this week, with dengue, EV71, MenB, and varicella programs all moving through regulatory or early clinical milestones [1][2][5][6].
- Several programs are still at proof-of-concept or early expansion stage, so the next inflection points are regulatory review, fuller efficacy data, and trial execution [2][3][5][6][7].
- Manufacturing readiness is becoming more visible alongside clinical progress, especially for Anixa’s Phase 2 planning and Takeda’s India commercialization pathway [1][7].
- IO Biotech’s shutdown is a reminder that late-stage oncology vaccines remain highly sensitive to endpoint results and regulator feedback [4].
- Monoclonal antibody prophylaxis, not just classic vaccination, is emerging as a preventive strategy, illustrated by Tonix’s Lyme program [3].
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Vaccine news from the past two weeks, curated by the LucidQuest team.
FAQ
What changed for Takeda’s Qdenga in India?
India’s Subject Expert Committee recommended import approval for Qdenga, but with a required post-marketing safety and effectiveness study in the local population after launch [1]. This is a regulatory step forward, not the final word on market rollout [1].
What is MVC trying to do with ENVACGEN in Malaysia?
MVC submitted an NDA to Malaysia’s NPRA for ENVACGEN, an EV71 vaccine already approved in Taiwan and Vietnam [2]. The filing extends the company’s ASEAN expansion strategy and targets HFMD prevention linked to EV71 [2].
Is Tonix’s TNX-4800 a vaccine?
Not exactly. TNX-4800 is a long-acting monoclonal antibody intended as a single-dose prophylactic against Lyme disease, targeting OspA on Borrelia burgdorferi [3]. Tonix says Phase 1 PK supports about four months of protection, with Phase 2 planned pending FDA clearance [3].
Why is IO Biotech shutting down?
BioSpace reports IO Biotech is winding down and filed for Chapter 7 after FDA feedback blocked an approval filing path for Cylembio [4]. The source ties this to a Phase 3 melanoma study that missed its primary endpoint [4].
What is notable about Delonix’s DX-104 study?
DX-104 has entered first-in-human Phase 1 testing in Australia, making it an early clinical validation step for Delonix’s OMV Plus platform [5]. The company positions the platform for broader bacterial vaccine programs beyond MenB [5].
What moved Anixa’s breast cancer vaccine closer to Phase 2?
Anixa cited positive final Phase 1 results and then signed Cytovance for cGMP manufacturing support for planned Phase 2 material supply [7]. The program targets α-lactalbumin, which the company says re-emerges in many breast cancers [7].
Entities / Keywords
Qdenga: Takeda dengue tetravalent vaccine, TDV, dengue vaccine, Takeda
ENVACGEN: MVC, EV71 vaccine, Enterovirus 71 vaccine, HFMD vaccine
TNX-4800: Tonix, Lyme prophylaxis, anti-Borrelia burgdorferi OspA monoclonal antibody, mAb 2217LS
Cylembio: IO Biotech, cancer vaccine, melanoma, pembrolizumab, Keytruda
DX-104: Delonix Bioworks, MenB vaccine, Group B meningococcal vaccine, OMV Plus
BARYCELA: GC Biopharma, varicella vaccine, chickenpox vaccine, two-dose varicella
Anixa breast cancer vaccine: Anixa Biosciences, Cleveland Clinic, α-lactalbumin vaccine, Cytovance Biologics
References